Table of Contents
Chapter 1. Global Biosimilar Market Executive Summary
1.1. Global Biosimilar Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Drug Class
1.3.2. By Indication
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Biosimilar Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Biosimilar Market Dynamics
3.1. Market Drivers
3.1.1. Launch of Novel Biosimilars
3.1.2. Strong R&D Pipeline
3.2. Market Challenges
3.2.1. Complexities in Manufacturing
3.2.2. Increased Competition and Regulatory Hurdles
3.3. Market Opportunities
3.3.1. Emerging Markets
3.3.2. Extended Therapeutic Uses
Chapter 4. Global Biosimilar Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Biosimilar Market Size & Forecasts by Drug Class 2022-2032
5.1. Segment Dashboard
5.2. Global Biosimilar Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Monoclonal Antibodies
5.2.2. Insulin
5.2.3. Granulocyte Colony-Stimulating Factor
5.2.4. Erythropoietin
5.2.5. Recombinant Human Growth Hormone
5.2.6. Etanercept
5.2.7. Follitropin
5.2.8. Teriparatide
5.2.9. Interferons
5.2.10. Anticoagulants
5.2.11. Other Drug Class
Chapter 6. Global Biosimilar Market Size & Forecasts by Indication 2022-2032
6.1. Segment Dashboard
6.2. Global Biosimilar Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Oncology
6.2.2. Inflammatory & Autoimmune Disorders
6.2.3. Chronic Diseases
6.2.4. Blood Disorders
6.2.5. Growth Hormone Deficiency
6.2.6. Infectious Diseases
6.2.7. Other Indications
Chapter 7. Global Biosimilar Market Size & Forecasts by Region 2022-2032
7.1. North America Biosimilar Market
7.1.1. U.S. Biosimilar Market
7.1.1.1. Drug Class breakdown size & forecasts, 2022-2032
7.1.1.2. Indication breakdown size & forecasts, 2022-2032
7.1.2. Canada Biosimilar Market
7.2. Europe Biosimilar Market
7.2.1. U.K. Biosimilar Market
7.2.2. Germany Biosimilar Market
7.2.3. France Biosimilar Market
7.2.4. Spain Biosimilar Market
7.2.5. Italy Biosimilar Market
7.2.6. Rest of Europe Biosimilar Market
7.3. Asia-Pacific Biosimilar Market
7.3.1. China Biosimilar Market
7.3.2. India Biosimilar Market
7.3.3. Japan Biosimilar Market
7.3.4. Australia Biosimilar Market
7.3.5. South Korea Biosimilar Market
7.3.6. Rest of Asia Pacific Biosimilar Market
7.4. Latin America Biosimilar Market
7.4.1. Brazil Biosimilar Market
7.4.2. Mexico Biosimilar Market
7.4.3. Rest of Latin America Biosimilar Market
7.5. Middle East & Africa Biosimilar Market
7.5.1. Saudi Arabia Biosimilar Market
7.5.2. South Africa Biosimilar Market
7.5.3. Rest of Middle East & Africa Biosimilar Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Orion Pharma AB
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Samsung Bioepis
8.3.3. Coherus BioSciences, Inc.
8.3.4. Eli Lilly and Company
8.3.5. Takeda Pharmaceutical Company Limited
8.3.6. Bristol-Myers Squibb Company
8.3.7. Merck KGaA
8.3.8. Teva Pharmaceutical Industries Ltd.
8.3.9. Biocon
8.3.10. Bayer AG
8.3.11. AbbVie Inc.
8.3.12. Allergan
8.3.13. Dr. Reddy's Laboratories Ltd.
8.3.14. Boehringer Ingelheim International GmbH
8.3.15. Biogen
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes